nocomments

The Link Between Pentosan Polysulfate Sodium and Serious Eye Damage

Research conducted by Emory Eye Center at the Emory School of Medicine in Atlanta found that longterm use of the drug pentosan polysulfate PPS (which is marketed under the name Elmiron) leads to a condition known as retinal maculopathy, or retinal injury, in some longterm users of pentosan polysulfate sodium. The study concludes that patients who undertook a longterm use regimen of pentosan polysulfate sodium to see an ophthalmologist for evaluation.

 

As Science Daily reports, “Last year, Nieraj Jain, M.D., of Emory Eye Center in Atlanta, Ga., reported that six patients who had been taking Elmiron for about 15 years had developed unusual changes in their macula, the central part of the retina responsible for delivering clear, crisp, central vison. Because nothing in the patients’ medical history or diagnostic tests explained the subtle, but striking pattern of abnormalities, Dr. Jain and his colleagues raised a warning flag that long-term use of Elmiron may damage the retina.”

 

Doctors prescribe Elmiron or pentosan polysulfate sodium to treat problems such as interstitial cystitis (bladder pain or discomfort), osteoarthritis, and for the prevention of blood clots. With regard to interstitial cystitis, Science Daily reports, “Interstitial cystitis causes chronic pain in the bladder and pelvis area. More than 1 million people in the United States, mostly women, are estimated to have the condition. Elmiron is the only FDA-approved pill to treat it. As a mainstay of treatment for decades, hundreds of thousands of people have likely been exposed to the drug.”

 

The occurrence of problems related to vision and patients who take Elmiron were first observed in a cohort of 60-year-old plus patients, all of whom were diagnosed with interstitial cystitis and taking the drug as part of a treatment. An article published in the November 2018 edition of Ophthalmology outlined this case in detail. Titled “Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium,”  the abstract concluded that if patients had not taken pentosan polysulfate sodium, then they would likely not experience the degenerative effects associated with pigmentary maculopathy.

 

There are three main or general types of pigmentary maculopathy looked at by the researchers in this study. These include DHRD (Doyne Honeycomb Retinal Dystrophy), macular degeneration brought on by aging, and cellophane maculopathy. The first type, DHRD, is an inherited maculopathy that results in “pale spots” in the center of the eye that can grow into the shape of a honeycomb while macular degeneration brought about by aging results in a clouded vision in the center of the eye. Cellophane maculopathy is when a clear scar tissue forms over the retina’s center, the area of the eye associated with visual ability and sensitivity to light intensity.

 

Aside from the research data, the Food and Drug Administration Adverse Event Reporting System (FAERS) received 100 reported cases of eye problems associated with patients taking pentosan polysulfate sodium with at least 22 of those cases being labeled as “serious” 866 ATTY Law reports. Of course, these aren’t the only problems and side effects associated with taking pentosan polysulfate sodium for long periods of time. Other conditions that were observed by research include vitelliform deposits, retina dark spots, parafoveal pigmented eye deposits, retinal pigment epithelium atrophy, hair loss, skin rashes, headaches, sleep disorders, GERD, bruising, and diarrhea.

 

Deposits of vitelliform are often recognized by physicians as one of the many signs of macular dystrophy while dark pigmented spots on the retina are typically spotted by eye doctors during a routine examination of a patient’s eyes. Parafoveal pigmented eye deposits occur when injury happens to the blood vessels and capillaries around the macula. The atrophy of the retinal pigment epithelium is often associated with aging and is when a patient’s retinal pigment begins to lose effectiveness. As for the other disorders associated with this phenomenon, they are self-explanatory.

 

Another finding is that the dosage amount of pentosan polysulfate sodium impacts the level or degree to which patients are reporting symptoms and their severity. Higher dosages of the drug are associated with an increased incidence of the problems reported, research shows. The typical drug amount administered was 300mg in 100mg tablets three times per day however doctors could prescribe as much as 1,000 to 1,500mg per day. The retinal cells in patients apparently absorb the toxic elements in this drug which leads to the various eye problems reported.

 

Commenting on the research by Drs. Vora, Patel, and Melles, Science Daily writes: “They found 140 patients who had taken an average of 5,000 pills each over the course of 15 years. Of those 140 patients, 91 agreed to come in for an exam. Drs. Vora, Patel, and Melles took detailed images of the back of their eyes and then divided the images into three categories: normal, possible abnormality, definite abnormality. Twenty-two of the 91 patients showed clear signs of drug toxicity. The rate of toxicity rose with the amount of drug consumed, from 11 percent of those taking 500 to 1,000 grams to 42 percent of those taking 1,500 grams or more.”

 

While the cohort studied was largely made up of older people, one patient began experiencing vision and eye problems as young as thirty years of age according to 866 ATTY Law. Dr. Robin A. Vora, MD, comments, “It’s unfortunate. You have a patient with a chronic condition like interstitial cystitis, for which there is no cure and no effective treatment. They get put on these medications because it’s thought to have few side effects and few risks, and no one thinks about it again. And year after year, the number of pills they’re taking goes up and up.”

 

Because of the limited number of treatment options for people with interstitial cystitis, Dr. Vora recommends annual screenings for macular degeneration in patients that are taking or who have taken pentosan polysulfate sodium. One silver lining to all of this is that if action is taken at an early enough stage then damage can be mitigated and even potentially reversed.

 

https://www.sciencedaily.com/releases/2019/10/191012141218.htm

 

https://www.ic-network.com/long-term-pentosan-elmiron-use-may-be-linked-to-retinal-disease/